Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 95,954	$ 63,380
Accounts receivable	46	5,021
Prepaid expenses and other current assets	3,536	2,076
Research and development incentives receivable	10,714	6,292
Total current assets	110,250	76,769
Property and equipment, net	2,152	1,818
Operating lease right-of-use assets	2,177
Other assets	1,481	3,039
Total assets	116,060	81,626
Current liabilities:
Accounts payable	1,992	1,887
Accrued expenses and other current liabilities	6,035	7,032
Deferred revenue, current portion	808	10
Total current liabilities	8,835	8,929
Warrant liability		4,804
Operating lease liabilities	1,416
Deferred revenue, net of current portion	9,055	14,625
Other long-term liabilities	1,429	897
Total liabilities	20,735	29,255
Commitments and contingencies (Note 12)
Shareholders’ equity (deficit):
Ordinary shares, £0.01 nominal value; 31,995,653 and 15,452,420 shares authorized at September 30, 2019 and December 31, 2018, respectively; 17,902,869 shares issued and outstanding at September 30, 2019; 898,678 shares issued and 814,728 shares outstanding at December 31, 2018	226	10
Additional paid-in capital	193,850	1,857
Accumulated other comprehensive loss	(2,607)	(1,751)
Accumulated deficit	(96,144)	(69,942)
Total shareholders’ equity (deficit)	95,325	(69,826)
Total liabilities, convertible preferred shares and shareholders’ equity (deficit)	$ 116,060	81,626
Series A Convertible Preferred Shares
Shareholders’ equity (deficit):
Convertible preferred shares		41,820
Series B1 Convertible Preferred Shares
Shareholders’ equity (deficit):
Convertible preferred shares		54,621
Series B2 Convertible Preferred Shares
Shareholders’ equity (deficit):
Convertible preferred shares		$ 25,756